Abiraterone acetate (ZYTIGA®, Janssen) with
prednisone/prednisolone after androgen deprivation therapy failure in
asymptomatic or mildly symptomatic metastatic castration-resistant prostate
cancer (mCRPC) significantly extends life compared with prednisone/prednisolone
alone.1
Statistically significant new data from the final analysis of
the COU-AA-302 trial including 4 years of follow-up1 were reported at the 2014 Annual
Meeting of the European Society for Medical Oncology.
The findings, presented by Charles Ryan, MD, show an unmatched
overall survival of 34.7 months with ZYTIGA® plus prednisone/prednisolone compared
with 30.3 months for prednisone/prednisolone alone,
providing an unrivalled 4.4 months extension of life. The pre-specified final
analysis was performed after 96% of expected deaths had occurred.1
